Thereby certify that this correspondence is being deposited with the United

COPY OF PAPERS ORIGINALLY FILED

Attorney Docket No.: 020093-000120US

stal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 On

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE CEIVED

F= + 2 4 2002

In re application of:

Gerald P. Murphy et al.

Examiner:

M. Davis

Application No.: 09/016,737

Filed: January 30, 1998

Art Unit:

1642

For: ISOLATION AND/OR

PRESERVATION OF DENDRITIC CELLS FOR PROSTATE CANCER

IMMUNOTHERAPY

AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Office Action mailed October 3, 2001, please amend the above-identified application as follows:

IN THE CLAIMS:

Kindly replace claims 23 and 31 with the following substitute claims. An Appendix showing all changes to these claims is attached to this amendment as required by 37 C.F.R. § 1.121(c).

(Four Times Amended) A composition comprising a cell 23. population having an increased number of human dendritic cells competent and able to activate T cells specific to a prostate antigen as compared to a cell population directly isolated from peripheral blood.

(Amended) The composition according to claim 23 comprising a cell population having at least 20 fold more dendritic cells competent to and able to